Welcome to our dedicated page for Vascular Biogenics Ltd. news (Ticker: vblt), a resource for investors and traders seeking the latest updates and insights on Vascular Biogenics Ltd. stock.
Vascular Biogenics Ltd. (Nasdaq: VBLT), commonly known as VBL Therapeutics, is a leading biotechnology company headquartered at 6 Yonatan Netanyahu Street, Yehud, Center District, Israel. The company is dedicated to the discovery, development, and commercialization of innovative therapies for treating cancer and immune-inflammatory diseases. Its mission is to transform the standard of care in oncology through precision medicines.
Recently, VBL Therapeutics has made significant strides in its corporate journey. On August 14, 2023, the company announced its financial results for the second quarter ending June 30, 2023, and provided updates on its ongoing merger with Notable Labs, Inc. This merger is seen as a pivotal move, aiming to combine VBL's cutting-edge technologies with Notable's Predictive Precision Medicines Platform. The merger is anticipated to create a robust entity focused on developing a pipeline of clinical-stage precision medicines.
On September 6, 2023, the company's registration statement on Form S-4 was declared effective by the U.S. Securities and Exchange Commission (SEC), marking a critical milestone towards completing the merger. Following the approval from VBL’s shareholders at the annual and special meeting held on October 12, 2023, the merger is expected to close around October 16, 2023. Post-merger, VBL will be renamed 'Notable Labs, Ltd.' and will trade under the new symbol 'NTBL' on the Nasdaq Capital Market.
The merger with Notable Labs is expected to leverage Notable's technology to enhance VBL’s existing pipeline, offering a promising future for patients and shareholders alike. The combined organization aims to advance precision medicines that could significantly improve patient outcomes in oncology.
VBL Therapeutics (Nasdaq: VBLT), a biotechnology company focused on developing innovative therapies for challenging solid tumors, announced that CEO Dror Harats will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation is scheduled for January 10 at 7:00 a.m. ET. VBL's lead candidate, ofranergene obadenovec (VB-111), is currently in a Phase 3 trial for platinum-resistant ovarian cancer. More information can be found on the company’s website.
VBL Therapeutics (Nasdaq: VBLT) has secured €17.5 million from the European Innovation Council (EIC) Accelerator, consisting of a €2.5 million grant and €15 million equity investment. This prestigious funding, awarded to only 9% of applicants, will support the clinical development and pre-commercialization of ofra-vec (VB-111), aimed at treating ovarian cancer. VBL is nearing the completion of enrollment in a Phase 3 trial for ofra-vec, with data expected in late 2022. The EIC's backing highlights the potential of ofra-vec to address unmet medical needs in cancer treatment.
VBL Therapeutics (Nasdaq: VBLT) reported a net loss of $6.5 million for Q3 2021, with revenues remaining steady at $0.2 million. The company has more than 85% enrollment in the Phase 3 OVAL study for VB-111 in platinum-resistant ovarian cancer, with top-line data expected in H2 2022. Additionally, VBL anticipates initiating a first-in-human trial for VB-601 targeting inflammatory disorders in the latter half of 2022. As of September 30, 2021, VBL had $50.8 million in liquid assets, sufficient to fund operations through Q4 2023.
VBL Therapeutics (Nasdaq: VBLT) announced it will release its third quarter financial results for the period ending September 30, 2021, on November 15, before market open. CEO Professor Dror Harats and CFO Sam Backenroth will host a conference call at 8:30 AM ET to discuss the results and provide a corporate update. VBL is focused on developing first-in-class therapeutics for challenging malignant solid tumors, with its lead candidate, ofranergene obadenovec, in a Phase 3 trial for platinum-resistant ovarian cancer.
VBL Therapeutics (Nasdaq: VBLT) has appointed Sam Backenroth as the new Chief Financial Officer (CFO), replacing Amos Ron, who retires but will remain as Corporate Secretary and advisor. Backenroth brings extensive experience in financial strategy within biotech, having recently served as CFO at NeuBase Therapeutics, where he raised around $100 million in equity capital. The company is expanding its U.S. operations in New York under Backenroth's leadership, aiming to enhance its financing and business development efforts to support ongoing clinical trials, including the Phase 3 OVAL study.
VBL Therapeutics (VBLT) announced that its OVAL Phase 3 trial for VB-111 in platinum-resistant ovarian cancer has successfully recruited over 320 patients, which is more than 80% of its target. The trial remains on track to complete enrollment by 1Q22. The independent Data Safety Monitoring Committee gave clearance to continue the study with no protocol changes. The trial aims for two primary endpoints: progression-free survival (PFS) and overall survival (OS), both of which could facilitate a biologics license application (BLA) if successfully met. Results for PFS are expected in late 2022.
TEL AVIV, Israel, Sept. 10, 2021 – VBL Therapeutics (NASDAQ: VBLT) has announced its participation in several upcoming industry conferences. The H.C. Wainwright 23rd Annual Global Investment Conference is set for September 13, 2021, with an on-demand fireside chat at 7:00 a.m. ET. VBL will also present at the Cell & Gene Therapy World Asia 2021 conference on September 15, focusing on their gene therapy product VB-111. Lastly, the company will join the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22. Webcasts will be available on the company’s Investor Relations page.
VBL Therapeutics (NASDAQ: VBLT) has received FDA CMC clearance for new batches of VB-111 produced at its Modiin, Israel facility, facilitating patient recruitment for ongoing trials. The OVAL Phase 3 trial on platinum-resistant ovarian cancer has achieved nearly 80% enrollment and is expected to complete by 1Q22. Anticipated results for progression-free survival (PFS) in 2H22 may align with a potential BLA submission, expediting the regulatory process.
VBL Therapeutics reported financial results for Q2 2021, highlighting a cash position of $57.2 million expected to fund operations until year-end 2023. A public offering raised $26.4 million, allowing for continued development of VB-111, now with an amended primary endpoint including progression-free survival (PFS). Despite increasing R&D expenses rising to $6.6 million, the company’s net loss widened to $8.0 million or ($0.12) per share, compared to ($0.14) per share in 2020. VBL anticipates key data and potential BLA submission for VB-111 in the upcoming year.
VBL Therapeutics (Nasdaq: VBLT) announced it will release its second-quarter financial results on August 16, 2021, before market open. The results will cover the period ending June 30, 2021, followed by a conference call at 8:30 AM EDT featuring CEO Professor Dror Harats and CFO Amos Ron to discuss the findings. VBL Therapeutics focuses on developing first-in-class treatments for cancer and inflammatory diseases, with its lead candidate VB-111 targeting platinum-resistant ovarian cancer in a Phase 3 trial.
FAQ
What is the market cap of Vascular Biogenics Ltd. (vblt)?
What does Vascular Biogenics Ltd. specialize in?
Where is Vascular Biogenics Ltd. located?
What recent corporate event did VBL announce?
What is the significance of the merger with Notable Labs?
When is the merger expected to be completed?
What will VBL be renamed after the merger?
What will be the new trading symbol for VBL after the merger?
What recent approvals did VBL receive for the merger?
Who is the CEO of VBL Therapeutics?
How will the merger benefit patients?
